

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



ASCENTAGE PHARMA GROUP INTERNATIONAL

亞盛醫藥集團

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 6855)

CLARIFICATION ANNOUNCEMENT GRANT OF AWARDS UNDER THE 2021 RSU SCHEME TO THE INDEPENDENT SELECTED PERSONS

Reference is made to the announcements of Ascentage Pharma Group International (the “**Company**”, together with its subsidiaries, the “**Group**”) dated February 2, 2021, May 21, 2021, May 26, 2021 and June 18, 2021 (collectively, the “**Announcements**”) in relation to, among other things, the proposed grant of RSUs under the 2021 RSU Scheme to the Independent Selected Persons. Unless otherwise defined, capitalized terms used herein shall have the same meanings as those defined in the Announcements.

GRANT OF AWARDS UNDER THE 2021 RSU SCHEME TO THE INDEPENDENT SELECTED PERSONS

As disclosed in the announcements of the Company dated May 21, 2021 and June 18, 2021, the Company will grant an aggregate of 374,692 RSUs under the 2021 RSU Scheme, representing 374,692 Shares to a total of 32 Independent Selected Persons, who are employees of the Group.

The Company wishes to clarify that the RSUs granted to the Independent Selected Persons would be satisfied upon exercise by the allotment and issuance of Shares to the Trustee to be held by the Trustee for such purpose under the mandate granted to the Directors by the Shareholders at the annual general meeting of the Company held on May 10, 2021 to allot, issue and deal with up to 20% of the then issued share capital of the Company, being the general mandate currently available to the Company.

For the avoidance of doubt, the proposed grant of RSUs to Dr. Sidransky and Mr. Zhu constitutes a non-exempt connected transaction of the Company under Chapter 14A of the Listing Rules and is subject to the reporting, announcement and independent shareholders' approval requirements.

GENERAL

The 2021 RSU Scheme does not involve the grant of options in respect of new shares or other new securities of the Company or any of its subsidiaries, and is therefore not within the scope of, and subject to, Chapter 17 of the Listing Rules.

Save as disclosed above, all other information as set out in the Announcements remain unchanged and shall continue to be valid for all purposes. This announcement should be read in conjunction with the Announcements.

By order of the Board
Ascentage Pharma Group International
Dr. Yang Dajun
Chairman and Executive Director

Suzhou, People's Republic of China, June 25, 2021

As at the date of this announcement, the Board of Directors of the Company comprises Dr. Yang Dajun as Chairman and executive Director, Dr. Wang Shaomeng, Dr. Tian Yuan, Dr. Lu Simon Dazhong and Mr. Liu Qian as non-executive Directors, and Mr. Ye Changqing, Dr. Yin Zheng, Mr. Ren Wei and Dr. David Sidransky as independent non-executive Directors.